- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12.11. | ELICERA THERAPEUTICS: Elicera's CEO: "One of the biggest milestones in our history" | 1 | Cision News | ||
| ELICERA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 12.11. | CERENO SCIENTIFIC: Elicera's CEO: "One of the biggest milestones in our history" | 2 | Cision News | ||
| 05.11. | Elicera Therapeutics includes the first patient in the Phase I/II clinical study CARMA targeting B-cell lymphoma | 1 | Cision News | ||
| 04.11. | Elicera Therapeutics will present at the BioStock Life Science Summit, November 20 | 5 | Cision News | ||
| 24.10. | Elicera Therapeutics enrolls the last patient in the clinical phase I/II-trial with oncolytic virus ELC-100 | 3 | Cision News | ||
| 03.09. | Elicera Therapeutics will participate in upcoming industry and investor conferences during the fall | 2 | Cision News | ||
| 29.08. | Elicera Therapeutics AB (publ) Interim Report 1 January - 30 June 2024 | 1 | Cision News | ||
| 17.06. | ELICERA THERAPEUTICS: Elicera teams up with China Medical University for cancer study | 2 | Cision News | ||
| 11.06. | Elicera Therapeutics enters a preclinical collaboration agreement with China Medical University for the development of ELC-201 | 1 | Cision News | ||
| 29.05. | ELICERA THERAPEUTICS: Elicera's first clinical CAR T-Cell study CARMA set to begin | 2 | Cision News | ||
| 27.05. | Elicera Therapeutics AB: Elicera Therapeutics AB (publ) Interim Report 1 January - 31 March 2024 | 316 | GlobeNewswire (Europe) | First quarter (January-March 2024)
Operating profit/loss amounted to SEK - 5,433,422 (-2,265,857).
Loss for the period amounted to SEK - 5,369,677 (-2,266,329).
Cash flow from operating activities... ► Artikel lesen | |
| 14.05. | Nasdaq Stockholm AB: Change of Certified Adviser for Elicera Therapeutics AB | 207 | GlobeNewswire | As from May 15, 2024, Elicera Therapeutics AB (publ) will change Certified
Adviser to Mangold Fondkommission AB.
This information is distributed at the request of the Certified Adviser,
Carnegie... ► Artikel lesen | |
| 04.04. | Nasdaq Stockholm AB: New equity right for trading, Elicera Therapeutics AB TO2 | 265 | GlobeNewswire | At the request of Elicera Therapeutics AB, Elicera Therapeutics AB equity
rights will be traded on First North Growth Market as from April 5, 2024.
Security name: Elicera Therapeutics AB TO2
-------------------------------------------
Short... ► Artikel lesen | |
| 27.03. | Nasdaq Stockholm AB: Last day of trading in paid subscription shares (BTU) of Elicera Therapeutics AB | 257 | GlobeNewswire | Trading in Elicera Therapeutics AB paid subscription units is to cease. The
last trading day is March 28, 2024.
Short name: ELIC BTU
ISIN code: SE0021626306
Orderbook ID: 324876
This information... ► Artikel lesen | |
| 23.02. | Nasdaq Stockholm AB: Listing of unit rights and paid subscription units of Elicera Therapeutics AB (91/24) | 548 | GlobeNewswire | With effect from February 26, 2024, the unit rights in Elicera Therapeutics AB
will be traded on First North Growth Market. Trading will continue up until and
including March 05, 2024.
Instrument:... ► Artikel lesen | |
| 19.02. | XFRA CAPITAL ADJUSTMENT INFORMATION - 19.02.2024 | 897 | Xetra Newsboard | Das Instrument CP6 US2166484020 COOPER COS INC. DL-,10 EQUITY wird cum Kapitalmassnahme gehandelt am 19.02.2024 und ex Kapitalmassnahme am 20.02.2024 The instrument CP6 US2166484020 COOPER COS INC.... ► Artikel lesen | |
| 13.02. | Elicera Therapeutics AB: Year-End Report 1 January - 31 December 2023 | 197 | GlobeNewswire (Europe) | Fourth quarter (October-December 2023)
Operating profit/loss amounted to SEK -5,212,694 (-3,951,799).
Loss for the period amounted to SEK -4,749,222 (-3,898,340).
Cash flow from operating... ► Artikel lesen |
17 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 9,685 | -2,22 % | Evotec: Extreme Ausschläge | Größer könnten die Gegensätze wohl kaum sein. Die Aktie von Evotec hat im zurückliegenden Jahren einen massiven Einbruch erfahren. Auf 52-Wochen-Sicht gehört sie zu den schlechtesten Aktien im SDAX.... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 709,80 | +0,65 % | Sanofi, Regeneron's Dupixent SBLA Accepted For FDA Review To Treat Chronic Spontaneous Urticaria | PARIS (dpa-AFX) - French drug major Sanofi (SNY) and Regeneron Pharmaceuticals, Inc. (REGN) announced Friday that the U.S. Food and Drug Administration has accepted for review the resubmission... ► Artikel lesen | |
| BRAIN BIOTECH | 3,110 | -2,51 % | Brain Biotech, DAX, Erste Group, Fielmann, Microsoft, TUI - 4investors Aktien Top-News | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| SCORPIUS | 0,050 | 0,00 % | Scorpius Holdings, Inc.: Scorpius Holdings Reports Third Quarter 2024 Results, Highlighting Strategic Partnerships, Cost Savings, and Progress Toward Profitability | DURHAM, N.C., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) ("Scorpius" or "the Company"), an integrated contract development and manufacturing organization ("CDMO")... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 1,450 | -2,16 % | Cardiol Therapeutics präsentiert klinische Ergebnisse der Phase-II-Pilotstudie MAvERIC zu rezidivierender Perikarditis bei den Scientific Sessions 2024 der American Heart Association | - Eine
deutliche und rasche Reduktion sowohl der Perikarditis-bedingten Schmerzen als auch der Entzündungen wurde während der 26-wöchigen Studie aufrechterhalten
- Anzahl... ► Artikel lesen | |
| BURCON NUTRASCIENCE | 0,113 | +9,71 % | Burcon NutraScience Corporation: Burcon Forms Alliance with Strategic Investor Group to Acquire Protein Production Facility | Vancouver, British Columbia--(Newsfile Corp. - November 20, 2024) - Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) ("Burcon" or the "Company"), a global technology leader in the development... ► Artikel lesen | |
| CSL | 169,82 | +1,91 % | Is CSL the best ASX 100 share to buy now? | ||
| MANNKIND | 6,692 | +2,58 % | MannKind Corp. Q3 Profit Increases, Beats Estimates | WASHINGTON (dpa-AFX) - MannKind Corp. (MNKD) revealed a profit for its third quarter that increased from last year and beat the Street estimates.The company's earnings totaled $11.55 million... ► Artikel lesen | |
| OCULAR THERAPEUTIX | 8,236 | -0,99 % | Ocular Therapeutix Inc reports results for the quarter ended September 30 - Earnings Summary | ||
| OXFORD NANOPORE TECHNOLOGIES | 1,454 | -4,22 % | Oxford Nanopore Technologies: Oxford Nanopore Announces Landmark UK Government Partnership to Advance Genomics-Driven Healthcare Innovation in the UK | New strategic partnership between UK Biobank, Genomics England, NHS England and Oxford Nanopore designed to: Advance biomedical research and translate discoveries for improved patient... ► Artikel lesen | |
| ADAPTIMMUNE THERAPEUTICS | 0,615 | -3,15 % | Adaptimmune nears second sarcoma approval as Phase II trial hits endpoints | ||
| CODEXIS | 4,122 | +0,19 % | Codexis, Inc.: Codexis Unveils Pioneering Enzymatic Synthesis Data to Enable the Future Manufacturing of RNAi Therapeutics | ||
| TELO GENOMICS | 0,089 | +15,69 % | Telo Genomics Corp.: Telo Genomics Receives Approval from the Intellectual Property Ontario Program (IPON) | Toronto, Ontario--(Newsfile Corp. - November 19, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") a biotech company developing the industry's leading telomere technology... ► Artikel lesen | |
| BIORA THERAPEUTICS | 1,640 | 0,00 % | Biora Therapeutics, Inc.: Biora Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results | Testing in advanced animal model planned in Q4 for smaller, 00-size BioJet device with largest capacity of any ingestible injectable Company granted extension until December 9 to regain compliance... ► Artikel lesen | |
| CORMEDIX | 10,500 | +2,94 % | CorMedix, Inc.: CorMedix Inc. Reports Third Quarter and Nine Month 2024 Financial Results and Provides Business Update | - Q3 2024 Net Revenue of $11.5 million - Commercializing DefenCath with Four of Top Five US Dialysis Providers - Conference Call Scheduled for Today at 8:30 a.m. Eastern Time BERKELEY HEIGHTS, N.J.... ► Artikel lesen |
ELICERA THERAPEUTICS AB gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,129 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ELICERA THERAPEUTICS AB finden Sie auf Wallstreet Online.
